Damora Therapeutics, Inc. (DMRA) Financial Statements
Free cash flow over the same period: -$6.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DMRADamora Therapeutics, Inc.Follow DMRA — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Research & development | 24.6 | 38.5 | 48.2 | 23.8 | 6.4 | 26.9 | 74.1 | |
| Operating income | -33.6 | -52.2 | -61.2 | -39.9 | -22.3 | -210.9 | -270.7 | |
| Pre-tax income | -34.8 | -51.8 | -61.6 | -38.3 | -21.4 | -209.8 | -262.5 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 | |
| Net income | -34.8 | -51.8 | -61.6 | -38.3 | -21.4 | -209.8 | -262.8 | |
| Diluted EPS ($) | -7.62 | -2.05 | -2.43 | -36.08 | -18.53 | 3.98 | -4.07 | |
| Diluted shares (mn) | — | — | 25.4 | 1.1 | 1.2 | 1.4 | — |
USD millions · SEC XBRL
Damora Therapeutics, Inc. — questions
- What is Damora Therapeutics, Inc.'s net income?
- -$262.8M over the twelve months to 2026-06-30.
- What is Damora Therapeutics, Inc.'s free cash flow?
- -$6.7M over the twelve months to 2026-06-30.
- What are Damora Therapeutics, Inc.'s diluted earnings per share?
- $-4.07 over the twelve months to 2026-06-30.
Every figure on this page comes from Damora Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.